Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects

Authors not listed

Tasly Pharmaceutical Group Co., Ltd · 2020

Abstract

The study is to evaluate the efficacy and safety of Sanhuangjingshimingwan in Wet AMD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Anonymous. (2020). A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects. <em>Tasly Pharmaceutical Group Co., Ltd</em>. https://clinicaltrials.gov/study/NCT04486963
Vancouver
Anonymous. A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects. Tasly Pharmaceutical Group Co., Ltd. 2020.
BibTeX
@misc{anon2020ARando, title = {A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects}, author = {Anonymous}, journal = {Tasly Pharmaceutical Group Co., Ltd}, year = {2020}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings